吸烟损害新辅助FOLFIRINOX对胰腺癌切除术后生存的获益
基于两个前瞻性机构数据库848例胰腺导管腺癌切除患者,其中357例(42.1%)接受新辅助治疗。多变量模型显示新辅助FOLFIRINOX与 active吸烟的交互作用与总生存下降风险最高相关(HR 2.35;95%CI 1.13-4.90),并强烈减弱FOLFIRINOX的获益(HR 0.40;95%CI 0.25-0.63)。
要点
- 新辅助FOLFIRINOX与吸烟交互作用与OS下降最高风险相关(HR 2.35;95%CI 1.13-4.90)。
- 吸烟强烈减弱新辅助FOLFIRINOX的生存获益(HR 0.40;95%CI 0.25-0.63)。
- FOLFIRINOX新辅助患者中,从不吸烟和既往吸烟者调整中位OS未达到,active吸烟者为26.2个月。
核心结论
- 本研究证实新辅助FOLFIRINOX与优异生存相关,并证明active吸烟会减弱其获益。
- 列线图可辅助日常临床实践,并强调胰腺导管腺癌患者戒烟的重要性,尤其是新辅助FOLFIRINOX之前。
研究设计与样本
- 从两个前瞻性机构数据库识别所有接受胰腺导管腺癌切除术的患者,提取临床病理数据及包括吸烟状态在内的人口学资料。
- 共纳入848例患者,357例(42.1%)接受新辅助治疗,491例(57.9%)直接切除,475例(56%)接受辅助治疗。
- 进行生存分析和多变量Cox回归建模,使用限制性立方样条定义线性数据的截断点。
主要发现
- 全队列、新辅助治疗后和直接切除后的中位总生存分别为27.8个月、36.1个月和23.0个月。
- 464例(54.7%)为从不吸烟者,250例(29.5%)为既往吸烟者,134例(15.8%)为active吸烟者。
- 多变量模型中,新辅助FOLFIRINOX与active吸烟的交互作用与总生存下降最高风险相关(HR 2.35;95%CI 1.13-4.90),并强烈减弱FOLFIRINOX的获益(HR 0.40;95%CI 0.25-0.63)。
- 接受FOLFIRINOX新辅助治疗的患者中,从不吸烟者和既往吸烟者的调整中位总生存未达到,active吸烟者为26.2个月。
- 基于该模型生成列线图,用以展示胰腺导管腺癌切除术后5年生存概率。
临床怎么用
- 列线图可辅助日常临床实践。
- 作者强调胰腺导管腺癌患者戒烟的重要性,尤其是新辅助FOLFIRINOX之前。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Smoking plays an important role in carcinogenesis, including pancreatic ductal adenocarcinoma (PDAC). However, little is known about the association between smoking status and prognosis in resected PDAC. METHODS: All patients who underwent resection for PDAC were identified from two prospective institutional databases. Clinicopathologic data as well as demographics including smoking status were extracted. Survival analysis and multivariable Cox regression modelling was performed. Restricted cubic splines were used for linear data to define cut-off points. RESULTS: Out of 848 patients, 357 (42.1%) received neoadjuvant treatment (NAT), 491 upfront resection (57.9%), and 475 (56%) adjuvant therapy. The median overall survival (OS) was 27.8 months, 36.1 months, and 23.0 months for the entire cohort, after NAT and upfront resection. 464 patients were never smokers (54.7%), 250 former smokers (29.5%), and 134 active smokers (15.8%). In the multivariable model, the interaction of neoadjuvant FOLFIRINOX and active smoking was associated with the highest risk for decreased OS (harzard ratio (HR) 2.35; 95% confidence interval 1.13-4.90) and strongly mitigated the benefit of FOLFIRNOX (HR 0.40; 95% CI 0.25-0.63). Adjusted median OS in NAT patients with FOLFIRINOX was not reached for never and former smokers, compared to 26.2 months in active smokers. Based on the model, a nomogram was generated to illustrate the probability of 5-year survival after PDAC resection. CONCLUSION: The present study confirms that neoadjuvant FOLFIRINOX is associated with excellent survival and demonstrates that active smoking reduces its benefit. The nomogram can assist in daily clinical practice and emphasises the importance of smoking cessation in patients with PDAC, especially prior to NAT with FOLFIRINOX.
引用
- Leonhardt CS, Pils D, Qadan M, et al. Smoking impairs the effect of neoadjuvant FOLFIRINOX on postresection survival in pancreatic cancer. Eur J Cancer. 2023. PMID: 37713740. doi:10.1016/j.ejca.2023.113293
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。